The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

III.c

Hemoptysis

When present (e.g. PMID 23544289), pulmonary opacities may reflect true DAH or be the mere consequence of hemoptysis

Publications

Nour SM, Nour HA, Mehta JB, Roy TM, Byrd RP Jr

Hemoptysis and respiratory failure following sildenafil use for pulmonary hypertension.

Tennessee medicine : journal of the Tennessee Medical Association. 2013;106(3):34-5

Maxey DM, Ivy DD, Ogawa MT, Feinstein JA

Food and Drug Administration (FDA) postmarket reported side effects and adverse events associated with pulmonary hypertension therapy in pediatric patients.

Pediatric cardiology. 2013;34(7):1628-36

Pereira e Silva JL, Araujo Neto CA, Marchiori E

Pulmonary hemorrhage after the use of sildenafil.

Heart & lung : the journal of critical care. 2012;41(4):407-8

Dixit R, Jakhmola P, Sharma S, Arya M, Parmej AR

Recurrent haemoptysis following sildenafil administration.

The Indian journal of chest diseases & allied sciences. 2009;51(2):119-20